Advanced in Polymorphous Low Grade Adenocarcinoma

Dr. Zujun Li

Oncology | Hematology
New York University
111 Broadway, 
New York, NY 
Offers Telehealth
Advanced in Polymorphous Low Grade Adenocarcinoma
New York University
111 Broadway, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zujun Li is an Oncologist and a Hematologist in New York, New York. Dr. Li is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Glioma, Laryngeal Cancer, Colorectal Cancer, and Throat Cancer.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006
Other Locations
NEW YORK UNIVERSITY
560 1st Ave, New York, NY 10016
NEW YORK UNIVERSITY
160 E 34th St, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: PDR001
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

A Phase II Exploratory Trial Evaluating CT-based Mid-Treatment Nodal Response to Select for De-escalated chemoradiation therapy in the definitive management of p16+ Oropharyngeal Cancer.
A Phase II Exploratory Trial Evaluating CT-based Mid-Treatment Nodal Response to Select for De-escalated chemoradiation therapy in the definitive management of p16+ Oropharyngeal Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: November 12, 2024
Similar Doctors
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Loren S. Michel
Oncology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Loren S. Michel
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (4.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Loren Michel is an Oncologist in New York, New York. Dr. Michel is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, Epithelial-Myoepithelial Carcinoma, and Glioma. Dr. Michel is currently accepting new patients.

Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Alan L. Ho
Oncology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Alan L. Ho
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (5.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Ho is an Oncologist in New York, New York. Dr. Ho is rated as an Elite provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Salivary Gland Tumors, Adenoid Cystic Carcinoma, Thyroid Cancer, and Follicular Thyroid Cancer.

Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Alison M. Schram
Oncology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Alison M. Schram
Oncology

Memorial Developmental Chemo Group

1275 York Ave, 
New York, NY 
 (4.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alison Schram is an Oncologist in New York, New York. Dr. Schram is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Lung Adenocarcinoma, and Epithelial-Myoepithelial Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 36 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile